New drug cocktail targets tough lung cancer
NCT ID NCT03333343
First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This study tests the safety and early effectiveness of combining the drug EGF816 with other targeted therapies (INC280, trametinib, ribociclib, gefitinib, or LXH254) in adults with advanced EGFR-mutant non-small cell lung cancer. About 105 participants will receive one of these combinations. The goal is to find better ways to control the disease, not to cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-MUTANT NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Ancona, AN, 60126, Italy
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Tainan, 704302, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
Conditions
Explore the condition pages connected to this study.